Literature DB >> 22981849

Maternal antibody parameters of cattle and calves receiving EG95 vaccine to protect against Echinococcus granulosus.

David D Heath1, Christine Robinson, Marshall W Lightowlers.   

Abstract

Cattle may act as hosts for the transmission of the cestode parasite Echinococcus granulosus and play a role in transmission of the parasite leading to human cystic echinococcosis (CE). The recombinant EG95 vaccine has been shown to be able to protect cattle and other intermediate host species against CE. Ideally the immunisation of bovines against E. granulosus, using EG95 vaccine, should occur early in life so as to provide maximum protection against the establishment of hydatid cysts. Maternally derived antibody from vaccinated cows may provide some protection for the neonate, but may also interfere with the active response to vaccination. Experiments were undertaken to determine the optimal regime for protection of young cattle against CE. One group of pregnant cattle received 2 vaccinations of EG95 antigen+Quil A adjuvant two months and one month prior to calving. The control group of pregnant cattle were not vaccinated. Calves were either challenged with E. granulosus eggs at 4, 9, 13 or 17 weeks post-birth or were given their first vaccination at 8, 12 or 16 weeks post-birth. Sera obtained at regular intervals were tested by ELISA to assess the immunological response. All calves were experimentally challenged with E. granulosus eggs and subsequent necropsy confirmed the levels of protection. Maternal antibody was shown to protect calves to some extent for at least 17 weeks. Calves from vaccinated cows responded well serologically if the first vaccination was given at 8 or 12 weeks, but full protection against a challenge infection was achieved only if the first vaccination was delayed until 16 weeks after birth. Calves from non-vaccinated cattle also were not fully protected if the first vaccination was at 8 or 12 weeks, but were fully protected if the first vaccination was given when they were 16 weeks old. This suggests that immunological maturity is not acquired in calves until 4 or 5 months of age. No safety problems were observed following two vaccinations of 40 pregnant cows or 30 suckling calves.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981849     DOI: 10.1016/j.vaccine.2012.08.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Identification, expression and phylogenetic analysis of EgG1Y162 from Echinococcus granulosus.

Authors:  Fengbo Zhang; Xiumin Ma; Yuejie Zhu; Hongying Wang; Xianfei Liu; Min Zhu; Haimei Ma; Hao Wen; Haining Fan; Jianbing Ding
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Immunoprotection of recombinant Eg.myophilin against Echinococcus granulosus infection in sheep.

Authors:  Mingxing Zhu; Fu Gao; Zihua Li; Xiuqing Wang; Hao Wang; Zhisheng Wang; Jiaqing Zhao; Wei Zhao
Journal:  Exp Ther Med       Date:  2016-07-05       Impact factor: 2.447

3.  Mechanism of protective immunity by vaccination with recombinant Echinococcus granulosus glutathione S-transferase (Chinese strain) in mice.

Authors:  Mingxing Zhu; Xiuqing Wang; Hao Wang; Zhisheng Wang; Jiaqing Zhao; Yana Wang; Wei Zhao
Journal:  Exp Ther Med       Date:  2015-06-18       Impact factor: 2.447

4.  The Recombinant Eg.P29-Mediated miR-126a-5p Promotes the Differentiation of Mouse Naive CD4+ T Cells via DLK1-Mediated Notch1 Signal Pathway.

Authors:  Xiancai Du; Mingxing Zhu; Tingrui Zhang; Chan Wang; Jia Tao; Songhao Yang; Yazhou Zhu; Wei Zhao
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

5.  Construction and identification of the recombinant plasmid pET30a-EgA31-Eg95 of Echinococcus granulosus.

Authors:  Yanhua Li; Fengbo Zhang; Mohammed H Althunayan; Xiao-An Hu; Yan Xin; Haiying Jia; Yuyuan Guo; Xiumin Ma; Hao Wen; Jianbing Ding
Journal:  Exp Ther Med       Date:  2013-11-07       Impact factor: 2.447

6.  Immunoprotection of recombinant Eg.P29 against Echinococcus granulosus in sheep.

Authors:  Hao Wang; Zihua Li; Fu Gao; Jiaqing Zhao; Mingxing Zhu; Xin He; Nan Niu; Wei Zhao
Journal:  Vet Res Commun       Date:  2016-04-19       Impact factor: 2.459

Review 7.  Use of Veterinary Vaccines for Livestock as a Strategy to Control Foodborne Parasitic Diseases.

Authors:  Valeria A Sander; Edwin F Sánchez López; Luisa Mendoza Morales; Victor A Ramos Duarte; Mariana G Corigliano; Marina Clemente
Journal:  Front Cell Infect Microbiol       Date:  2020-06-26       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.